Connect with us

Cannabis

Innocan’s Over-The-Counter Pain Relief Spray Receives FDA’s Technical Validation for Marketing in the USA

Newsfile

Published

on

Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – July 13, 2020) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (the “Company” or “Innocan“), is pleased to announce that it has received notice from the FDA that Innocan’s over-the-counter Relief & Go Pain Relief spray product has successfully received technical validation and approval to commence marketing in the USA. Innocan’s pain relief formulation contains a combination of Magnesium oil, Methyl salicylate, Menthol and CBD. The Relief & GO Pain Relief spray is designed to target pain-related muscle and provide relief for joint pain. The unique formulation is administered with a simple dose of spray, roll-on or lotion.

Cannot view this image? Visit: https://i0.wp.com/grassnews.net/wp-content/uploads/2020/07/innocans-over-the-counter-pain-relief-spray-receives-fdas-technical-validation-for-marketing-in-the-usa.jpg?w=740&ssl=1

Figure 1

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6922/59564_2ac31f7bc4361a4d_002full.jpg

“We are excited to receive the approval from the FDA to market our flagship pain relief product in the USA” Iris Bincovich, co-founder and CEO of Innocan states and she continues: “This represents the Company’s ability to develop and practice breakthrough technologies to create new CBD based products for the growing pain relief market.”

According to the American Academy of Pain Medicine chronic pain affects approximately 1.5 billion people worldwide, and research by Prescient & Strategic Intelligence reported that “Chronic Pain Treatment Market to Reach US $105.9 Billion by 2024”.

About Innocan

The Company, through its wholly owned subsidiary, Innocan Pharma Ltd. (“Innocan Pharma Israel”), is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”). InnoCan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus. CBD-Loaded Exosomes hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. This product, which is expected to be administrated by inhalation, will be tested against a variety of lung infections.

The Company signed on a worldwide exclusive license agreement with Yissum, the commercial arm of the Hebrew University of Jerusalem to develop CBD drug delivery platform based on a unique-controlled release Liposome to be administrated by Injection. The company plans, together with Prof. Berenholtz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University to test the Liposome platform on several potential indications. The company is also working on a dermal product integrating CBD with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals, including, but not limited to, topical treatments for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain. The founders and officers of InnoCan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

For further information, please contact:

For InnoCan Pharma Corporation:
Iris Bincovich, CEO
+972-54-3012842
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Certain information set forth in this news release, including, without limitation, the effectiveness and safety of the Company’s products, , information regarding the markets, requisite regulatory approvals and the anticipated timing for market entry, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond InnoCan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by InnoCan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of requisite production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: general global and local (national) economic, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import / export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner) and availability in each market of product inputs and finished products. The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of launch of product distribution. A comprehensive discussion of other risks that impact InnoCan can also be found in InnoCan’s public reports and filings which are available under InnoCan’s profile at www.sedar.com.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. InnoCan Pharma does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/59564

Cannabis

Benchmark Provides Update on Financial Condition of Potanicals

Newsfile

Published

on

Vancouver, British Columbia–(Newsfile Corp. – October 23, 2020) – Benchmark Botanics, Inc. (CSE: BBT) (“Benchmark” or the “Company”) Benchmark announces that the ongoing working capital deficiency of Potanicals Green Growers Inc. (“Potanicals“), the Company’s wholly owned subsidiary, may result in Potanicals being unable to meet all of its accounts payable at October 31, 2020, including its October 31, 2020 payroll obligations for all 39 of Potanicals’ employees, which will cause material uncertainty about Potanicals’ ability to continue as a going concern. During the period from January 1, 2019 to December 31, 2019, Potanicals had a net loss of approximately $1,736,000. As at October 22, 2020, Potanicals had cash of $102,493, and a working capital deficiency of $134,605.

The Company is actively exploring various options to address the financial difficulty issues of Potanicals, including increasing its sales from inventory, cutting its costs, restructuring its operations, and undertaking an equity or debt financing. To meet such funding requirements, if the Company closes an additional equity financing, it would be dilutive to existing shareholders. Debt financing, if available, may also involve restrictions on financing and operating activities. There is no assurance that such additional financing will be available on terms acceptable to the Company or at all. If the Company is unable to obtain additional financing as needed, it may be required to reduce the scope of the operations of Potanicals or any planned expansion. No assurances can be given that the Company will be able to raise the additional funding that may be required for such activities. The Company will provide further updates on this matter as it develops.

About Benchmark

Benchmark is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical and recreational markets in Canada. The Company’s business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp throughout Asia, in countries where it is legal to do so.

Benchmark is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint.

Benchmark’s 100% owned subsidiary, Potanicals Green Growers Inc. (“Potanicals) is a Health Canada licensed producer under the Cannabis Act and its regulations. The Company is producing at its indoor Peachland, BC Cannabis Complex and is constructing a Phase II expansion of an additional 10,000 square foot extraction facility there. Along with cultivation and production, the company’s Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetic improvements.

As part of its expansion strategy, the company and a joint venture partner completed a second facility, a 4-acre Greenhouse Operation in Pitt Meadows, BC. The Company, through Potanicals, has received its second cultivation license, effective November 29, 2019, from Health Canada for the Pitt Meadow greenhouse.

For further information, please visit the Company’s website at www.benchmarkbotanics.com or the Company’s profile at www.sedar.com.

If you would like to be added to Benchmark’s news distribution list, please sign up at Investor Relations info@bbtinc.ca.

ON BEHALF OF THE BOARD OF

BENCHMARK BOTANICS INC.
“William Ying”

William Ying
Chief Executive Officer

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.

Forward-Looking Statements

This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66763

Continue Reading

Cannabis

PURA Addresses Next Steps to Issue Dividend of PAOG Stock

Newsfile

Published

on

Dallas, Texas–(Newsfile Corp. – October 23, 2020) – Puration, Inc. (OTC Pink: PURA) today announced that PURA management and PAO Group, Inc. (OTC Pink: PAOG) management have scheduled combined efforts next week to complete the joint documentation and submission requirements necessary to execute the planned dividend of PAOG stock to PURA shareholders. A joint PURA and PAOG announcement is scheduled for next Friday, October 30, 2020. The dividend update announcement comes today in conjunction with the overall corporate update scheduled for release today and included in its entirety below:

Corporate Update

Last month, PURA introduced Farmersville Brands and announced a major juncture in the company’s growth and development as the company pivots from its hemp derived CBD beverage industry foundation to launch a Texas flavored, holistic lifestyle branded approach into a broader, but still niche, $20 billion sector within an overall market worth at least $2 trillion.

January of this year, PURA launched an acquisition campaign as a forerunner initiative to the Farmersville Brands transition.

Since launching the acquisition campaign in January, the company has acquired a CBD confections business, a CBD pet products business and CBD sun care business. Combined with its existing beverage industry product line, PURA’s combined horizontal market opportunity ranges across over $2 trillion in market value:

Sexual wellness $39 Billion Projected Market Value

Confections $232 Billion Projected Market Value

Pet Products $202 Billion Projected Market Value

Sun Care $12.6 Billion Projected Market Value

Non-Alcoholic Beverage $1.6 Trillion Projected Market Value

Central to the Farmersville Brands transition is the construction of a lifestyle brand that embodies the values, interests, attitudes, and opinions of the population where CBD and hemp products are an ideal fit.

Farmersville Brands holistic lifestyle approach will include a certain Texas personality component built on a targeted 72-acre property in Farmersville, Texas, just north of Dallas, expected to soon be acquired by PURA.

The location is intended to be a hemp mecca were visitors can participate in and learn about the reintroduction of hemp into the American market. Visitors can engage on a recreational weekend sojourn, or engage in a professional capacity to explore the best agricultural and processing practices, and new innovative methods for utilizing hemp to construct homes or to power cars.

Earlier this week, on Wednesday, PURA announced executing a contract to purchase the 72-acre farmland parcel located in Farmersville, TX, for a consideration of $1.3 million. This is a key step in the Farmersville Brand strategy transition.

PURA also has a planned $100 million investment strategy developing to fund the Farmersville transition. The company is keeping details under wraps at the moment but anticipates making the plan pubic before year end.

PAOG Dividend Next Steps

PAO Group, inc. (OTC Pink: PAOG) recently acquired a hemp cultivation business from PURA. PAOG is building a partnership with PURA in conjunction with PAOG’s new hemp cultivation business. PAOG has announced working with PURA’s new hemp processing facility in Farmersville, Texas where the two companies will partner on the construction of a greenhouse for cultivating pharmaceutical grade hemp and a lab for CBD extraction.

PAOG’s partnership includes making PURA shareholders, shareholders of PAOG. PAOG’s purchase of PURA included a PAOG stock issued to PURA shareholders in a dividend distribution. The timing of the execution of the dividend has been impacted by PAOG’s overall large volume of work surrounding the integration of its recently acquired RespRx CBD treatment for Chronic Obstructive Pulmonary Disease (COPD) and its newly acquired hemp cultivation operations. PAOG and PURA management have committed time together next week to get the dividend process over the speed bump. A joint progress announcement is planned for a week from today, next Friday, October 30, 2020.

For more information on Puration, visit http://www.purationinc.com

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66751

Continue Reading

Cannabis

PAOG Signs Clinical Research Organization (CRO) to Advance Respiratory Cannabis Treatment Through Regulatory Approval

Newsfile

Published

on

Sandusky, Ohio–(Newsfile Corp. – October 23, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG signed the agreement yesterday, prior to the comprehensive corporate update scheduled for publication today and included in its entirety below.

Corporate Update

Less than 90 days ago, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) and began to transform the company into a cannabis biopharmaceutical development operation. The company has come a long way very quickly and management believes the rapid progress has been possible based on the merits of the research backing RespRx.

RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled, “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT”.

In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated affecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.

The CRO agreement signed yesterday is a year long agreement and a major step forward to advancing RespRx through the regulatory approval process. PAOG plans to make a joint announcement next week with the CRO company.

As previously announced, and in addition to the CRO agreement announced today, PAOG continues to develop pharmaceutical research and development relationships in Puerto Rico’s burgeoning, recently reinvigorated pharmaceutical industry. An announcement of an anticipated key contract in Puerto Rico is expected soon.

Part of PAOG’s pharmaceutical development strategy includes the development of a proprietary hemp cultivar. In addition to acquiring RespRx from KALY, PAOG recently acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA). PAOG is building a partnership with PURA in conjunction with PAOG’s new hemp cultivation business. PAOG has announced working with PURA’s new hemp processing facility in Farmersville, Texas where the two companies will partner on the construction of a greenhouse for cultivating pharmaceutical grade hemp and a lab for CBD extraction.

PAOG’s partnership includes making PURA shareholders, shareholders of PAOG. PAOG’s purchase of PURA included a PAOG stock issued to PURA shareholders in a dividend distribution. The timing of the execution of the dividend has been impacted by the overall large volume of work surrounding the integration of the RespRx and hemp cultivation operations and the prioritization of establishing a CRO contract. PAOG and PURA management have committed time together next week to get the dividend process over the speed bump. A joint progress announcement is planned for a week from today, next Friday, October 30, 2020.

www.paogroupinc.com

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION:

Jim DiPrima
888-272-6472
info@pao.group

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66743

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania